This study is in progress, not accepting new patients

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

a study on Critical Limb Ischemia Peripheral Arterial Disease

Summary

healthy people welcome
at San Francisco, California
study started

Description

Summary

The purpose of this study is to understand the effects of fish oil supplement (containing parts of omega-3 fatty acids) on inflammation. The investigators are aiming to identify which dose of the fish oil supplement is the most effective. The name of the fish oil supplement is "SPM Emulsion."

Details

The OMEGA-SPM-DOSE trial and the OMEGA-SPM-PAD trial are two parts of a pilot study which aims to investigate the effect of a novel formulation of a nutritional supplement containing highly concentrated n-3 PUFA metabolites (SPM Emulsion) on the metabolo-lipidomic profile of healthy volunteers and patients with PAD. Ten healthy volunteers and ten patients with PAD will participate in Part 1a, the "OMEGA-SPM-DOSE Study". A follow-up, placebo controlled, prospective study on the best dosing modality determined in Phase 1a will then take place in a wider PAD population (n=30), Phase 1b - the "OMEGA-SPM-PAD Study". Specific measurements will include targeted metabolo-lipidomic profiling, established markers of inflammation, and functional monocyte and macrophage assays. The proposed studies have the potential to provide important new insights on the role of nutritional interventions in PAD.

Keywords

Critical Limb Ischemia Peripheral Artery Disease Ischemia Peripheral Arterial Disease

Eligibility

You can join if…

Healthy Volunteers:

  • Age 20-80

PAD Patients:

  • Mild claudication to rest pain (Rutherford 1-4)
  • Resting or exercise ABI < 0.9 or TBI < 0.6
  • Age 40 and more

You CAN'T join if...

PAD Patients and healthy volunteers:

  • Plan to undergo surgical procedure or PVI for treatment of PAD within one month
  • Evidence of active infection
  • Hypersensitivity or allergy to fish or seafood
  • Already on n-3 PUFA or equivalent
  • Chronic liver disease, end-stage renal disease (CKD 5), or chronic inflammatory disorders
  • Poorly controlled diabetes (HbA1C > 8%)
  • BMI < 20 or >35
  • Recent other major surgery or illness within 30 days
  • Use of immunosuppressive medications or steroids
  • History of organ transplantation
  • Pregnancy, or plans to become pregnant, or lactating

Healthy Volunteers:

  • hsCRP > 2mg/L
  • Regular aspirin use
  • Regular non-steroidal anti-inflammatory drug use

Location

  • University of California San Francisco
    San Francisco, California, 94143, United States

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT02719665
Phase
Phase 1
Lead Scientist
Michael Conte
Study Type
Interventional
Last Updated
October 25, 2017

© The Regents of the University of California